KAILERA THERAPEUTICS INC
KLRANASDAQTrading Snapshot
- Day Range
- $13.30 – $13.83
- 52-Week Range
- $9.76 – $28.23
- Volume (shares)
- 1,037,482
- Avg Volume (shares)
- —
- Shares Outstanding
- 129.6M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
KAILERA THERAPEUTICS INC
KLRAFinancial history unavailable.
StockOtter · stockotter.spaceAbout KAILERA THERAPEUTICS INC
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What Happened
Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s stock price was up 7.6% on Friday. The stock traded as high as $10.76 and last traded at $10.76. 293,082 shares were traded during mid-day trading, a decline
Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?
Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s share price reached a new 52-week low on Monday. The stock traded as low as $10.20 and last traded at $10.20, with a volume of 51759 shares. The stock had pre
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01,
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Could this be what Novo needs to turn things around?
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, 202
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6%